However, results from trials using intranasal OXT in patients with schizophrenia have been mixed, some reporting improvement of positive and negative symptoms or improvement of specific deficits, while others reported no benefit (Feifel et al., 2016; Bradley and Woolley, 2017). The gene discussed is OXT; the disease is schizophrenia.